Strands

Premium

Isis Begins Phase I Trial of Antisense Drug for Diabetes

Isis Pharmaceuticals said this week that it has begun a phase I study of an antisense-based drug for type II diabetes.

The drug, called ISIS-SGLT2Rx, is designed to inhibit the production of sodium dependent glucose co-transporter type 2, which the company said is the major transporter responsible for glucose re-absorption in the kidney.

“Decreasing SGLT2 levels promotes glucose excretion in the urine and reduces blood sugar levels,” the company noted.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.